Skip to main content

Table 2 Comparison between the PTEN gene and protein evaluation methods for clinical endpoints of the HCRP cohort

From: PTEN loss in Gleason grade 7 prostate tumors exhibits intratumoral heterogeneity and is associated with unfavorable pathological features

 

FISH (n = 41)

IHC (n = 39)

Homo

Hemi

Intact

P

Loss

Intact

P

Age

62

66

62

0.50

62

62.5

0.77

Time to Biochemical Recurrencea

45

87

83.5

0.37

82

84

0.52

Preoperative PSA

15.5

12.4

7.08

0.47

10.9

7.57

0.46

Gleason Score

 3 + 4

2

1

30

0.001*

5

28

0.29

 4 + 3

1

4

3

2

4

Pathological Stage

 2

1

5

27

0.09

4

28

0.08

 3

2

0

6

3

4

Positive Surgical Margins

 No

0

4

23

0.04*

3

22

0.66

 Yes

3

1

10

4

10

Perineural Invasion

 No

2

1

12

0.42

5

10

0.08

 Yes

1

4

21

2

22

Extraprostatic Extension

 No

1

5

27

0.09

4

28

0.08

 Yes

2

0

6

3

4

Vesicle Invasion

 No

2

5

30

0.32

6

30

0.45

 Yes

1

0

3

1

2

Biochemical Recurrencea

 No

2

4

25

0.76

5

26

0.24

 Yes

1

1

5

2

3

Gleason Score Upgrade

 No

1

2

15

0.02*

2

16

0.40

 3 + 4

1

0

15

3

12

 4 + 3

1

3

3

2

4

  1. Median per group for time to biochemical recurrence is shown in months. Median of preoperative PSA levels are shown in ng/mL. Median of age at surgery is indicated in years. Kruskal-Wallis test was used to compare continuous variables for FISH data and Mann-Whitney test for IHC data. Categorical variables were compared through Fisher’s exact test. *P < 0.05. aData available for 40 patients. FISH fluorescence in situ hybridization, IHC immunohistochemistry, Homo Homozygous deletion, Hemi Hemizygous deletion
Back to article page

Applied Cancer Research

ISSN: 1980-5578